Back

Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials

10 May 2026 (14:48 - 14:57)
Organised by: Logo
Congress Presentation Part of: Novel and targeted therapies: precision pharmacology in heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Guiomar Mendieta Badimon

Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

4 More presentations in this session

Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract
Presentation thumbnail
The influence of QRS duration and resynchronization status on the efficacy and safety of omecamtiv mecarbil in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Assistant Professor M. Ruppert (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effect of aficamten compared with metoprolol in women versus men: analysis of MAPLE-HCM
Doctor X. Wang (Boston, US)
Abstract Slides Video
Presentation thumbnail
Ferric carboxymaltose modulates metabolic and inflammatory pathways alongside erythropoiesis in heart failure: mechanistic insights from the AFFIRM-AHF
Doctor N. Grote Beverborg (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and targeted therapies: precision pharmacology in heart failure
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 14:48 CET
You may be interested in
thumbnail
Congress Presentation
Anti-inflammatory agents
thumbnail
Congress Session
Novel and targeted therapies: precision pharmacology in heart failure
thumbnail
Congress Presentation
Emerging anti-inflammatory therapies for heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources